Kenai Therapeutics Secures $82M Series A to Develop Off-the-Shelf Neuron Replacement Cell Therapy for Parkinson’s

- Kenai Therapeutics, formerly Ryne Bio, receives $82 million Series A funding.
- Lead candidate, RNDP-001, is an iPSC-derived dopamine progenitor cell therapy for Parkinson's disease.
- The financing will help submit an IND for RNDP-001, commence Phase I trials, and further develop the pipeline.
- Notable investors include Alaska Permanent Fund Corporation, The Column Group, Cure Ventures, Saisei Venture, and Euclidean Capital.
- Preclinical studies show robust survival, innervation, and behavioral rescue data for RNDP-001.